Nemea recently expanded its portfolio with the introduction of its new UniSpray, a single-dose nasal spray that administers systematic-acting pharmaceuticals. The ready-to-use device delivers a single liquid dose of 100µL that can be self-administered by patients to treat a range of health conditions.
Bernhard Rohn, VP of strategy and marketing at Nemera, comments: “Nemera has a long-standing experience in the nasal delivery route, focusing until now on multidose pumps. Adding UniSpray to our product range provides additional options for our customers and patients, answering the needs of the single-metered dose spray combination products.”
The Nemea UniSpray meets the increased consumer demand for nasal drug delivery. More patients prefer this method thanks to its easy administration and improved efficacy.
Image Credit: Nemea
What's Driving This Trend
- Single-dose Nasal Sprays
- More pharmaceutical companies may invest in developing single-dose nasal spray devices as a convenient and efficient method for delivering systemic-acting medication.
- Self-administered Medication
- The emergence of single-dose nasal spray devices may lead to more patients being able to self-administer medication for a range of health conditions at home.
- Increased Consumer Demand for Nasal Drug Delivery
- Pharmaceutical companies could capitalize on the growing popularity of nasal drug delivery by introducing more innovative solutions, like single-dose nasal sprays.
Who This Affects Most
- Pharmaceuticals
- This technology could revolutionize the pharmaceutical industry by providing a convenient and efficient method for delivering systemic-acting medication.
- Healthcare
- The development of single-dose nasal spray devices could help improve patient outcomes by enabling more patients to self-administer medication at home.
- Medical Devices
- The emergence of single-dose nasal spray devices opens up opportunities for medical device companies to innovate and introduce new products that meet the growing consumer demand for nasal drug delivery.
